Published Date: 15 Mar 2023
Since the development of functional magnetic resonance imaging in the 1990s, expectations for neuroimaging have skyrocketed as researchers analyze fMRI data of the resting brain and the body of the brain unique to it.
Read Full NewsTafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer
2.
MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information
3.
Prostate cancer mortality is significantly reduced when docetaxel is used.
4.
Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC
5.
Medical Journal March 28, 2023
1.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
2.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
3.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
4.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
5.
Nuclear Medicine's Role in Battling Women's Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
4.
Efficient Management of First line ALK-rearranged NSCLC - Part V
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation